References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailBackground for studies on the treatment of male osteoporosis: state of the art.
Kaufman, J M; Johnell, O; Abadie, Eric ULg et al

in Annals of the Rheumatic Diseases (2000), 59(10), 765-72

Male osteoporosis represents an important, although long underestimated, public health problem. Both in men and in women aging is accompanied by continuous bone loss and by an exponential increase in the ... [more ▼]

Male osteoporosis represents an important, although long underestimated, public health problem. Both in men and in women aging is accompanied by continuous bone loss and by an exponential increase in the incidence of osteoporotic fracture, with a female to male incidence ratio of about 2 to 3 to 1 in the elderly for hip and vertebral fractures. Morbidity after osteoporotic fractures appears to be more serious and mortality more common in men than in women. To date, no single treatment has been proved to be effective and safe in published prospective studies. The present report, based on a systematic search of the literature on male osteoporosis, summarises the state of the art on the clinical consequences of male osteoporosis and its risk factors, in relation to the present state of knowledge about female osteoporosis. This constitutes the background for the design of rational clinical development strategies for therapeutic interventions in male osteoporosis. From this review of the literature it is apparent that notwithstanding the existing sex differences in pathophysiology of osteoporosis and the difference in age-specific incidence of osteoporotic fractures, there are also important similarities between osteoporosis in women and men. The higher incidence of fracture in women than in men results from quantitative differences in risk factors rather than from different risk factors. Even though there are sex differences in bone geometry, incidence of fracture seems to be similar in men and women for a same absolute areal bone mineral density. However, the lack of data on the changes in fracture rates in men resulting from pharmacological intervention, leading to changes in bone mineral density or bone turnover, remains the main limitation for extrapolation of established treatment outcomes from women to men. [less ▲]

Detailed reference viewed: 34 (4 ULg)
Full Text
Peer Reviewed
See detailLes propriétés de la glucosamine
Reginster, Jean-Yves ULg; Halkin, V

in Journal de Pharmacie de Belgique (2000), 55(5), 118-121

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporose bij de bejaarde
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sfeer (2000), 103

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailEigenschappen van glucosamine
Reginster, Jean-Yves ULg; Halkin, V

in Medi-Sfeer (2000), 116

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailInterest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry
Ben Sedrine, Wafa ULg; Devogelaer, JP; Kaufman, JM et al

in Osteoporosis International (2000), SS(S5), 13

Detailed reference viewed: 35 (9 ULg)
Full Text
Peer Reviewed
See detailLa chondroprotection aujourd’hui
Reginster, Jean-Yves ULg; Ethgen, Olivier ULg; Dang Vu, T

in Rhumatologie (2000), 52(8), 13-16

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailConception actuelle du traitement de l’arthrose
Reginster, Jean-Yves ULg; Henrotin, Yves ULg

in Revue de la Médecine Générale [=RMG] (2000), 177

Detailed reference viewed: 43 (1 ULg)
Full Text
Peer Reviewed
See detailLe capital osseux : une épargne qui débute au berceau
Halkin, V; Reginster, Jean-Yves ULg

in L'agenda Pédiatrie (2000), 22

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailBases scientifiques du traitement physique de la gonarthrose
Henrotin, Yves ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in KINE 2000 (2000), 11(4), 86-94

Detailed reference viewed: 21 (7 ULg)
Full Text
Peer Reviewed
See detailHet botkapitaal : een spaarboekje dat in de wieg begint
Halkin, V; Reginster, Jean-Yves ULg

in De Agenda Pediatrie (2000), 22

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPreventie van postmenopauzale osteoporose
Reginster, Jean-Yves ULg; Halkin, V

in De agenda Gynaecologie (2000), 19

Detailed reference viewed: 2 (1 ULg)
Full Text
Peer Reviewed
See detailIsokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis
Henrotin, Yves ULg; Croisier, Jean-Louis ULg; Dumont, R et al

in Annals of the Rheumatic Diseases (2000), 59(S1), 275

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailIntensive and prolonged health promotion strategy may increase self-reported osteoporosis prevalence among postmenopausal women
Tellier, V; De Maeseneer, J; Cartier, P et al

in Annals of the Rheumatic Diseases (2000), 59(S1), 58

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
REGINSTER, Jean-Yves ULg; Minne, H. W.; Sorensen, O. H. et al

in Osteoporosis International (2000), 11(1), 83-91

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with ... [more ▼]

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease. [less ▲]

Detailed reference viewed: 20 (13 ULg)
Full Text
Peer Reviewed
See detailInterest of a simple pre-screening test for optimizing the cost/benefit value of bone densitometry
Ben Sedrine, Wafa ULg; Broers, Ph; Brands, G et al

in Osteoporosis International (2000), SS(S5), 13

Detailed reference viewed: 23 (5 ULg)